30th Oct 2019 17:32
GlaxoSmithKline plc (the 'Company')
Transaction notification
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr Jonathan Symonds | |||
b) | Position/status | Non-Executive Chairman
| |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2019 to 30 September 2019.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £17.25 | 833.830 |
| ||
|
|
|
| ||
d) | Aggregated information
| n/a (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-10-30 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr Vindi Banga | |||
b) | Position/status | Senior Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2019 to 30 September 2019.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £17.25 | 416.667 |
| ||
|
|
|
| ||
d) | Aggregated information
| n/a (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-10-30 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr Vivienne Cox | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2019 to 30 September 2019. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £17.25 | 307.971 |
| ||
|
|
|
| ||
d) | Aggregated information
| n/a (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-10-30 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms Lynn Elsenhans | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |||
b) | Nature of the transaction | Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2019 to 30 September 2019.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| $44.27 | 1,117.592 |
| ||
|
|
|
| ||
d) | Aggregated information
| n/a (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-10-30 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr Laurie Glimcher | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |||
b) | Nature of the transaction | Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2019 to 30 September 2019.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| $44.27 | 1,241.769 |
| ||
|
|
|
| ||
d) | Aggregated information
| n/a (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-10-30 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Dr Jesse Goodman | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |||
b) | Nature of the transaction | Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2019 to 30 September 2019.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| $44.27 | 374.672 |
| ||
|
|
|
| ||
d) | Aggregated information
| n/a (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-10-30 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms Judy Lewent | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | American Depositary Shares ('ADSs')
ISIN: US37733W1053
| |||
b) | Nature of the transaction | Acquisition of notional ADSs under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2019 to 30 September 2019.
| |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| $44.27 | 417.491 |
| ||
|
|
|
| ||
d) | Aggregated information
| n/a (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-10-30 | |||
f) | Place of the transaction
| n/a | |||
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr Urs Rohner | |||
b) | Position/status | Independent Non-Executive Director | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares')
ISIN: GB0009252882
| |||
b) | Nature of the transaction | Acquisition of notional Ordinary Shares under the share allocation arrangements for Non-Executive Directors for the period of service from 1 July 2019 to 30 September 2019. | |||
c) | Price(s) and volume(s) |
| Price(s) | Volume(s) |
|
| £17.25 | 416.667 |
| ||
|
|
|
| ||
d) | Aggregated information
| n/a (single transaction) | |||
Aggregated volume Price |
| ||||
e) | Date of the transaction | 2019-10-30 | |||
f) | Place of the transaction
| n/a | |||
Related Shares:
Glaxosmithkline